PATENT CLAIM ANALYSIS

Application Number: 16010419
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "070110"]

Abstract:
Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Claim (Index 8):
The functionalized polymer of  claim 4 , wherein said B1 is a monoclonal antibody selected from abciximab, adalimumab, alefacept, alemtuzumab, alirocumab, apatinib, arcitumomab, atezolizumab, avelumab, basiliximab, belimumab, besilesomab, bevacizumab, bezlotoxumab, brentuximab, brodalumab, canakinumab, capromab, catumaxomab, certolizumab, cetuximab, daclizumab, daratumumab, denosumab, dinutuximab, dupilumab, durvalumab, eculizumab, efalizumab, efalizumab, elotuzumab, evolocumab, fanolesomab, gemtuzumab, golimumab, herceptin adc, ibritumomab, ibritumomab tiuxetan, idarucizumab, imiciromab, inflectra, infliximab, ipilimumab, ixekizumab, lifirafenib, mepolizumab, muromonab-cd3, natalizumab, necitumumab, nivolumab, nofetumomab, obiltoxaximab, obinutuzumab, ocrelizumab, ofatumumab, olaratumab, omalizumab, osimertinib, palivizumab, pamiparib, panitumumab, pembrolizumab, pertuzumab, pyrotinib, ramucirumab, ranibizumab, raxibacumab, reslizumab, rituximab, rituximab, satumomab, secukinumab, shr1210m, shr-a1201, siltuximab, sulesomab, tislelizumab, tocilizumab, tositumomab, trastuzumab, ustekinumab, vedolizumab, votumumab, or zanubrutinib; a cytokine selected from an interleukin, interferon \u03b12a or interferon \u03b1; a hormone selected from granulocyte colony stimulating factor (GCSF), insulin, glucagon, glucagon like peptide-1, erythropoietin or follicle stimulating hormone; a ligand of cell surface receptors; a lectin; nucleic acids selected from an siRNA, a ribozyme, antisense nucleic acids, naked nucleic acids, a CpG oligonucleotide (ODN); a virus; or a virus-like particle; and said B2 comprises a taxane, a paclitaxel, a gemcitabine, a camptothecin, anthracyclines, doxorubicin, epirubicin, cisplatin, carboplatin, vinorelbine, capecitabine, ixabepilone or eribulin.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 94.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15352521', '15818742', '12833988', '12833991', '12834029']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7732131387403648
- 35 USC 102 Novelty (BERT): 0.572259517134827
- Combined Prediction Score: 0.7531177765798109
- Mean Citation Score: 320.420716
- Max Citation Score: 525.5287
- Similarity Product: 337.61897759072184

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test